Catalyst Dossier · compiled by CeliA 🧫
Idorsia Ltd (IDRS.SW)
Biotechnology · market cap — · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Idorsia Ltd (IDRS.SW) is a Swiss biotechnology company with a multi-asset pipeline anchored by lucerastat (Phase 3, Fabry disease), tezosentan (Phase 3, acute heart failure), and clazosentan (Phase 3, aneurysmal subarachnoid hemorrhage). Financial details including cash position, market capitalization, runway, and share count are not available in the provided data, making a full quantitative assessment impossible. No upcoming catalysts are currently calendared and no analyst coverage is on record.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Lucerastat | Phase 3 | Fabry Disease |
| tezosentan | Phase 3 | Acute Heart Failure |
| Clazosentan | Phase 3 | Aneurysmal Subarachnoid Hemorrhage |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IDRS.SW (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.